Hypertension: Is there always a cause?

Abstract
Elevated blood pressure and consequently systemic hypertension (HTN) are common. HTN was divided into either essential, which counts for more than 90% of cases (where the patient needs a medication for life), and secondary (less than 10% of cases). In clinical practice, when we Look at blood pressure as a vital sign, the elevation of blood pressure is always secondary, where there is always a cause behind its elevation. During our clinical practice and observation, this complex vital sign should be approached in a totally different manner, where solving the cause or at least targeting it, can achieve early diagnosis, better survival and reduction in the number of anti-hypertensive medication if not stopping all of them. In this article we proposed a new classification and approach for hypertensive patients and reviewed the different etiologies behind the elevation in blood pressure.

Keywords
Hypertension. causes of hypertension. secondary hypertension. resistant hypertension.

Cite this paper
Ali H. EL Masri, Hypertension: Is there always a cause? , SCIREA Journal of Clinical Medicine. Volume 8, Issue 5, October 2023 | PP. 392-418. 10.54647/cm321205

References

[ 1 ]	J Hypertens 2019 Sep;37(9):1813-1821. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries Pablo Lamelas 1 , Rafael Diaz 2 , Andres Orlandini 2 , Alvaro Avezum 3 , Gustavo Oliveira 3 , Antonio Mattos 3 , Fernando Lanas 4 , Pamela Seron 4 , Maria J Oliveros 4 , Patricio Lopez-Jaramillo 5 , Johanna Otero 5 , Paul Camacho 5 , Jaime Miranda 6 , Antonio Bernabe-Ortiz 6 , German Malaga 6 , Vilma Irazola 7 , Laura Gutierrez 7 , Adolfo Rubinstein 7 , Noelia Castellana 2 , Sumathy Rangarajan 1 , Salim Yusuf 1 .
[ 2 ]	Lancet 2017; 389:37–55. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants.
[ 3 ]	Lancet 2005; 365:217–223. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data.
[ 4 ]	Curr Hypertens Rep. 2019 Apr 5; 21(5): 34. Sleep and Resistant Hypertension. Mercedes R. Carnethon1 and Dayna A. Johnson2.
[ 5 ]	NEJM, February 2023, Vol. 38, number 5, Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension Mason W. Freeman, M.D., Yuan-Di Halvorsen, Ph.D., William Marshall, M.D., Mackenzie Pater, Ph.D., Jon Isaacsohn, M.D., Catherine Pearce, D.H.Sc., Brian Murphy, M.D., M.P.H., Nicholas Alp, M.D., Ajay Srivastava, M.D., Deepak L. Bhatt, M.D., M.P.H., and Morris J. Brown, M.D., for the BrigHTN Investigators.
[ 6 ]	Centers for Disease Control and Prevention. Estimated hypertension prevalence, treatment, and control among U.S. adults. Atlanta: Department of Health and Human Services, 2021 (https://million hearts.hhs.gov/data-reports/hypertension -prevalence.html).
[ 7 ]	Current Diabetes Reports volume 11, pages 64–69 (2011). Resistant Hypertension and Sleep Apnea: Pathophysiologic Insights and Strategic Management. Stephen K. Williams, Joseph Ravenell, Girardin Jean-Louis, Ferdinand Zizi, James A. Underberg, Samy I. McFarlane & Gbenga Ogedegbe .
[ 8 ]	Cells. 2020 Jan; 9(1): 50. Atherosclerosis and the Capillary Network; Pathophysiology and Potential Therapeutic Strategies. Tilman Ziegler,1,2 Farah Abdel Rahman,1 Victoria Jurisch,1 and Christian Kupatt1,2,* .
[ 9 ]	Am J Epidemiol. 1990; 131:423–433. Mitchell B.D., Stern M.P., Haffner S.M., Hazuda H.P., Patterson J.K. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study.
[ 10 ]	Can J Cardiol. 2018 May; 34(5): 575–584. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. John R. Petrie, MD, PhD, Tomasz J. Guzik, MD, PhD, and Rhian M. Touyz, MD, PhD.
[ 11 ]	J Am Coll Cardiol 1999; 34: 631-638. Anderson TJ. Assessment and Treatment of Endothelial Dysfunction in Humans.
[ 12 ]	J Atheroscler Thromb. 2018 Jan 1; 25(1): 27–39. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. Naoto Katakami1,2 .
[ 13 ]	Antioxid Redox Signal. March 2021; 34(9): 736–749. Roles of Perivascular Adipose Tissue in Hypertension and Atherosclerosis. Hengjing Hu,1 Minerva Garcia-Barrio,2 Zhi-sheng Jiang,1 Yuqing Eugene Chen,2 and Lin Chang2 .
[ 14 ]	European Society of Cardiology, Journals, E-Journal of Cardiology Practice, Microvascular angina and systemic hypertension, Vol. 14, N° 2 - 26 Jan 2016. Prof. Juan Carlos Kaski, FESC. Dr. Christiana Vitale.
[ 15 ]	Am J Cardiovasc Drugs. 2004;4(3):179-94. Kaski JC, Aldama G, Cosín-Sales J. Cardiac syndrome X. Diagnosis, pathogenesis and management.
[ 16 ]	Adv Pharmacol. 2018; 81: 241–330. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Xi Wang and Raouf A. Khalil.
[ 17 ]	Clin Chem Lab Med. 2004; 42:121–131. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
[ 18 ]	Angiology. 2005; 56:173–189.Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications.
[ 19 ]	Biochem Pharmacol. 2014b; 89:370–385. Li W, Mata KM, Mazzuca MQ, Khalil RA. Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy.
[ 20 ]	J Clin Med. 2020 Sep; 9(9): 2880. Coronary Microvascular Dysfunction. Federico Vancheri,1,* Giovanni Longo,2 Sergio Vancheri,3 and Michael Henein4,5,6.
[ 21 ]	Curr. Opin. Cardiol. 2007; 22:316–320. Landmesser U., Drexler H. Endothelial function and hypertension.
[ 22 ]	Gimelli A., Schneider-Eicke J., Neglia D., Sambuceti G., Giorgetti A., Bigalli G., Parodi G., Pedrinelli R., Parodi O. Homogeneously Reduced Versus Regionally Impaired Myocardial Blood Flow in Hypertensive Patients: Two Different Patterns of Myocardial Perfusion Associated With Degree of Hypertrophy. J. Am. Coll. Cardiol. 1998; 31:366–373.
[ 23 ]	Eur. Heart J. 2018; 39:840–849. Taqueti V.R., Solomon S.D., Shah A.M., Desai A.S., Groarke J.D., Osborne M.T., Hainer J., Bibbo C.F., Dorbala S., Blankstein R., et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
[ 24 ]	Eur. Heart J. 2020; 41:2376–2378. Escaned J., Lerman L.O. Coronary microcirculation and hypertensive heart failure.
[ 25 ]	Hypertension. 2021 Nov; 78(5): 1197–1205. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Guanghong Jia1,3 and James R. Sowers1,2,3 .
[ 26 ]	European Society of Cardiology, Journals, e-Journal of Cardiology Practice, E-Journal of Cardiology Practice - Volume 4, Obesity related hypertension. An article from the e-journal of the ESC Council for Cardiology Practice, Vol. 4, N° 21 - 07 Feb 2006. Prof. Guido Grassi.
[ 27 ]	Am J Cardiovasc Dis. 2021; 11(4): 504–529. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Robert J Henning.
[ 28 ]	Int J Obes (Lond) 2016; 40:761–767. Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez F. Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999-2004.
[ 29 ]	Curr Opin Clin Nutr Metab Care. 2015; 18:535–551. Prado C, Gonzalez M, Heymsfi eld S. Body composition phenotypes and obesity paradox.
[ 30 ]	J Physiol Pharmacol 2015; 66:367-72. Gibas-Dorna M, Nowak D, Piatek J, Pupek-Musialik D, Krauss H, Kopczynski P. Plasma ghrelin and interleukin-6 levels correlate with body mass index and arterial blood pressure in males with essential hypertension.
[ 31 ]	Cardiovasc Drugs Ther 33:501–509, 2019. Kagota S, Maruyama-Fumoto K, Shimari M, McGuire JJ, and Shinozuka K. Angiotensin II type 1 receptor antagonist azilsartan restores vascular reactivity through a perivascular adipose tissue-independent mechanism in rats with metabolic syndrome.
[ 32 ]	Hypertension 70: 780–789, 2017. Sakaue T, Suzuki J, Hamaguchi M, Suehiro C, Tanino A, Nagao T, Uetani T, Aono J, Nakaoka H, Kurata M, Sakaue T, Okura T, Yasugi T, Izutani H, Higaki J, and Ikeda S. Perivascular adipose tissue angiotensin II type 1 receptor promotes vascular inflammation and aneurysm formation.
[ 33 ]	N Engl J Med. 2004 Dec 23;351(26):2683-93. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. Lars Sjöström 1, Anna-Karin Lindroos, Markku Peltonen, Jarl Torgerson, Claude Bouchard, Björn Carlsson, Sven Dahlgren, Bo Larsson, Kristina Narbro, Carl David Sjöström, Marianne Sullivan, Hans Wedel, Swedish Obese Subjects Study Scientific Group.
[ 34 ]	Curr Hypertens Rep. 2019 Jun 24;21(8):63. Hypertension as a Metabolic Disorder and the Novel Role of the Gut. Masami Tanaka 1, Hiroshi Itoh 2 .
[ 35 ]	N Engl J Med 2019; 381:1046-57. Treatment of Hypertension in Patients with Asthma Sandra C. Christiansen, M.D., and Bruce L. Zuraw, M.D.
[ 36 ]	J Asthma 2007; 44:849-54. The relationship between age of asthma onset and cardiovascular disease in Canadians. Dogra S, Ardern CI, Baker J.
[ 37 ]	J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):76-81. Hypertension and Asthma: A Comorbid Relationship. Sandra C Christiansen 1, Michael Schatz 2, Su-Jau Yang 3, Eunis Ngor 3, Wansu Chen 3, Bruce L Zuraw 4 .
[ 38 ]	N Engl J Med 2020; 382:353-63. Treating Hypertension in Chronic Obstructive Pulmonary Disease Shannon W. Finks, Pharm.D., Mark J. Rumbak, M.D., and Timothy H. Self, Pharm.D.
[ 39 ]	Am J Physiol Regul Integr Comp Physiol. 2013 Nov 1;305(9): R1031-9. Knockdown of tyrosine hydroxylase in the nucleus of the solitary tract reduces elevated blood pressure during chronic intermittent hypoxia. Chandra Sekhar Bathina 1, Anuradha Rajulapati, Michelle Franzke, Kenta Yamamoto, J Thomas Cunningham, Steve Mifflin.
[ 40 ]	J Atheroscler Thromb. 2017 Sep 1; 24(9): 884–894. The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases. Hajime Abe,1 Hiroaki Semba,1,2 and Norihiko Takeda1 .
[ 41 ]	Curr Hypertens Rep. 2016; 18(3): 19. Neural Control of Blood Pressure in Chronic Intermittent Hypoxia. Brent Shell, Katelynn Faulk, and J. Thomas Cunningham .
[ 42 ]	Curr Cardiol Rep. 2017; 19(11): 110. Sleep and Cardio-Metabolic Disease. Francesco P. Cappuccio1,2 and Michelle A. Miller1 .
[ 43 ]	J Glob Health 2018 Jun;8(1): 010405.Association of obstructive sleep apnea with hypertension: A systematic review and meta-analysis. Haifeng Hou 1 2 3, Yange Zhao 4 3, Wenqing Yu 4 3, Hualei Dong 5, Xiaotong Xue 5, Jian Ding 5, Weijia Xing 1 3, Wei Wang 1 2 3 .
[ 44 ]	J Clin Hypertens (Greenwich). 2018 Mar; 20(3): 592–605. Subjective sleep quality, blood pressure, and hypertension: a meta‐analysis. Kenneth Lo, BSc, 1 Brigitte Woo, BN, 2 Martin Wong, BSc, 3 and Wilson Tam, PhD 2.
[ 45 ]	Int J Environ Res Public Health. 2021 Jul 25;18(15):7867. Relationship between Sleep and Hypertension: Findings from the NHANES (2007-2014). Chunnan Li 1 , Shaomei Shang 1 .
[ 46 ]	Vnitr Lek, 2020 Fall;66(7):415-419. Obstructive sleep apnea and hypertension: the role of gut microbiome. Pavel Šiarnik, Katarína Klobučníková, Imrich Mucska, Alžbeta Hlucháňová, Oto Hanus, Peter Turčáni, Branislav Kollár.
[ 47 ]	American Journal of Hypertension, Volume 31, Issue 8, August 2018, Pages 857–864. Sleep Disorders, Including Sleep Apnea and Hypertension Emer Van Ryswyk, Sutapa Mukherjee, Ching Li Chai-Coetzer, Andrew Vakulin, R Doug McEvoy .
[ 48 ]	Sleep Med Rev. 2018; 41:3–38. Insomnia and hypertension: a systematic review. Jarrin DC, Alvaro PK, Bouchard MA, Jarrin SD, Drake CL, Morin CM.
[ 49 ]	Sleep Med Rev. 2017; 33:70–8. The role of race and ethnicity in sleep, circadian rhythms and cardiovascular health. Egan KJ, Knutson KL, Pereira AC, von Schantz M.
[ 50 ]	Curr Hypertens Rep. 2014;16(1): 411. The role of obesity and obstructive sleep apnea in the pathogenesis and treatment of resistant hypertension. Marcus JA, Pothineni A, Marcus CZ, Bisognano JD.
[ 51 ]	Annu Rev Psychol. 2015; 66:143–72. Why sleep is important for health: a psychoneuroimmunology perspective. Irwin MR.
[ 52 ]	Curr Hypertens Rep. 2018;20(9):74. Sympathetic nervous system, sleep, and hypertension. Seravalle G, Mancia G, Grassi G.
[ 53 ]	Ageing Res Rev. 2016;26: 96–111. Hypertension and aging. Buford TW.
[ 54 ]	Sleep. 2011 Nov 1; 34(11): 1487–1492. Sleep Duration and Sleep Quality in Relation to 12-Year Cardiovascular Disease Incidence: The MORGEN Study. Marieke P. Hoevenaar-Blom, MSc,1,2 Annemieke M.W. Spijkerman, PhD,1 Daan Kromhout, MPH, PhD,2 Julia F. van den Berg, PhD,3 and W.M. Monique Verschuren, PhD1 .
[ 55 ]	Hypertension. 2011 Oct; 58(4): 596–603. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Maple M. Fung, MD,1,2 Katherine Peters,3 Susan Redline, MD,4 Michael G. Ziegler, MD,2 Sonia Ancoli-Israel, PhD,5 Elizabeth Barrett-Connor, MD,6 and Katie L. Stone, PhD3, for the Osteoporotic Fractures in Men (MrOS) Research Group
[ 56 ]	Sleep Breath. 2020; 24(1): 351–356. Sleep and hypertension. B. Han,1 W. Z. Chen,2 Y. C. Li,2 J. Chen,2,3 and Z. Q. Zeng2
[ 57 ]	Santos ESGD, Souza OF. Evidence of the association between sleep duration and blood pressure in adolescents: a systematic review. Rev Paul Pediatr. 2021; 39: e2019225.
[ 58 ]	Arch Argent Pediatr 2021;119(4):245-250 / 245 Prevalence of sleep-disordered breathing among adolescents and its association with the presence of obesity and hypertension. Javier A. Fraire, M.D., a,b Noelia M. Deltetto, M.D.,a Fabrizio Catalani, B.S.,c,d Analisa Beneitez, Student,c,d Lucía Martín, B.S.,c,d Daniela Fischman, M.D.,c,d Alicia B. Orden, M.D.e,f and Marcos Mayer, M.D.d,e,g.
[ 59 ]	Nat Commun. 2021; 12: 963. Renal metabolism and hypertension. Zhongmin Tian1 and Mingyu Liang2 .
[ 60 ]	The Anatomical Record, 2019 Nov. 15, Human nephron number, hypertension, and renal pathology. Go Kanzaki, Nobuo Tsuboi, Akira Shimizu, Takashi Yokoo.
[ 61 ]	Hypertension. 2010 May;55(5):1116-22. Effect of sodium loading/depletion on renal oxygenation in young normotensive and hypertensive men. Menno Pruijm 1, Lucie Hofmann, Marc Maillard, Sylvie Tremblay, Nicolas Glatz, Gregoire Wuerzner, Michel Burnier, Bruno Vogt.
[ 62 ]	Nephrology (Carlton). 2018 Oct; 23: 44–49. Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease. Qi Qian 1 .
[ 63 ]	71- Clin Sci (Lond). 2021 Sep 17; 135(17): 2165–2196. Autoimmune-mediated renal disease and hypertension. Erika I. Boesen and Rahul M. Kakalij.
[ 64 ]	Nat Commun. 2017; 8:14037. CD8(+) T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension Liu Y, Rafferty TM, Rhee SW, Webber JS, Song L, Ko B, et al.
[ 65 ]	Hypertension. 2015;65(3):569–76. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma−/− and interleukin-17A−/− mice. Kamat NV, Thabet SR, Xiao L, Saleh MA, Kirabo A, Madhur MS, et al.
[ 66 ]	Am J Physiol Regul Integr Comp Physiol. 2010;299(2): R590–5. Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Li K, Guo D, Zhu H, Hering-Smith KS, Hamm LL, Ouyang J, et al.
[ 67 ]	Hypertension. 2016;68(1):167–74. Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension. Norlander AE, Saleh MA, Kamat NV, Ko B, Gnecco J, Zhu L, et al.
[ 68 ]	Endocrinol Metab Clin North Am. 2019 Dec; 48(4): 765–778. Renovascular Hypertension. Sandra M Herrmann, MD, Assistant Professor of Medicine1 and Stephen C Textor, MD, Professor of Medicine1
[ 69 ]	Front Physiol. 2017; 8: 845. Gut–Brain Axis in Regulation of Blood Pressure. Tao Yang and Jasenka Zubcevic* .
[ 70 ]	Curr. Hypertens. Rep. 2011; 13, 303–308. 10. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Grassi G., Seravalle G., Dell'Oro R., Mancia G.
[ 71 ]	Circulation Research. 2014; 114:1804–1814. The Autonomic Nervous System and Hypertension. Giuseppe Mancia and Guido Grassi.
[ 72 ]	Hypertension. 1999; 34:724–728. Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage. Giuseppe Mancia, Guido Grassi, Cristina Giannattasio and Gino Seravalle.
[ 73 ]	Hypertension. 2009; 54:690–697. Assessment of Sympathetic Cardiovascular Drive in Human Hypertension. Achievements and Perspectives. Guido Grassi.
[ 74 ]	Hypertension. 1989; 14: 177–183. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Anderson EA, Sinkey CA, Lawton WJ, Mark AL.
[ 75 ]	Hypertension. 1998; 31: 68–72. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G.
[ 76 ]	J Hypertens. 2000; 18: 587–593. Mancia G. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. Grassi G, Seravalle G, Bertinieri G, Turri C, Dell'Oro R, Stella ML,
[ 77 ]	N Engl J Med. 1996; 335: 1480–1485. Preeclampsia - a state of sympathetic overactivity. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE.
[ 78 ]	Hypertension. 2007; 50: 537–542. Neurogenic abnormalities in masked hypertension. Grassi G, Seravalle G, Quarti Trevano F, Dell'Oro R, Bolla G, Cuspidi C, Arenare F, Mancia G.
[ 79 ]	Am J Hypertens. 2004; 17: 217–222. Relationship between central sympathetic activity and stages of human hypertension. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA.
[ 80 ]	Hypertension. 2008; 52: 925–931. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G.
[ 81 ]	J Hypertens. 2007; 25: 2280–2285. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white coat, masked and sustained hypertension versus true normotension. Fagard RH, Stolarz K, Kuznetsova T, Seidlerova J, Tikhonoff V, Grodzicki T, Nikitin Y, Filipovsky J, Peleska J, Casiglia E, Thijs L, Staessen JA, Kawecka-Jaszcz K.
[ 82 ]	European Society of Cardiology, Journals, E-Journal of Cardiology Practice - Volume 13. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. An article from the e-journal of the ESC Council for Cardiology Practice. Vol. 13, N° 36 - 24 Nov 2015. Prof. Guido Grassi
[ 83 ]	Circ Res. 2015 Mar 13;116(6):976-90. The sympathetic nervous system alterations in human hypertension. Grassi G, Mark A, Esler M.
[ 84 ]	Hypertension. 1988; 11 (6 Pt 2): 608-612. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Somers VK, Mark AL, Abboud FM.
[ 85 ]	Hipertens Riesgo Vasc. 2021 Apr-Jun;38(2):83-90. Psychosocial stress, high blood pressure and cardiovascular risk, Q Foguet-Boreu 1, L Ayerbe García-Morzon 2 .
[ 86 ]	Am J Hypertens. 2015 Nov; 28(11): 1295–1302. State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease. Beth E. Cohen, 1 , 2 Donald Edmondson, 3 and Ian M. Kronish 3
[ 87 ]	Arch Fam Med 1997; 6:43–49. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Jonas BS, Franks P, Ingram DD.
[ 88 ]	Hypertens Res. 2022 May;45(5):856-865. Anxiety, home blood pressure monitoring, and cardiovascular events among older hypertension patients during the COVID-19 pandemic. Shuyuan Zhang # 1, Yixuan Zhong # 1, Lixin Wang # 2, Xinhua Yin # 3 4, Yufeng Li 5, Yunlan Liu 6, Qiuyan Dai 7, Anli Tong 8, Dongfeng Li 9, Liangqing Zhang 10, Ping Li 11, Guohui Zhang 12, Rongjie Huang 13, Jinguang Liu 14, Luosha Zhao 15, Jing Yu 16, Xinjun Zhang 17, Li Yang 18, Jun Cai 19, Weili Zhang 20; STEP Study Group
[ 89 ]	Biomed Eng Online. 2022; 21: 19. Association between mental illness and blood pressure variability: a systematic review. Nur Husna Shahimi,1,2 Renly Lim,3 Sumaiyah Mat,2,4 Choon-Hian Goh,5 Maw Pin Tan,2,4 and Einly Lim1 .
[ 90 ]	Br J Pharmacol. 2019 Jun; 176(12): 1897–1913. Mechanisms of hypertension in autoimmune rheumatic diseases. Erin B. Taylor, 1 Victoria L. Wolf, 1 Elena Dent, 1 and Michael J. Ryan 1 , 2 .
[ 91 ]	Nature Reviews. Nephrology, (2014). 10(1), 56–62. Autoimmunity in the pathogenesis of hypertension. Rodríguez‐Iturbe, B., Pons, H., Quiroz, Y., Lanaspa, M. A., & Johnson, R. J.
[ 92 ]	Nephrology (Carlton), 18(4), 243–255. (2013). The role of cytokines in the pathogenesis of systemic lupus erythematosus—From bench to bedside. Yap, D. Y., & Lai, K. N.
[ 93 ]	PLoS ONE, 3(11), e3742. (2008). Potential relevance of alpha (1) ‐adrenergic receptor autoantibodies in refractory hypertension. Wenzel, K., Haase, H., Wallukat, G., Derer, W., Bartel, S., Homuth, V., Lindschau, C.
[ 94 ]	Hypertension, 62(1), 126–133. (2013). Immunosenescent CD8+ T cells and C‐X‐C chemokine receptor type 3 chemokines are increased in human hypertension. Youn, J. C., Yu, H. T., Lim, B. J., Koh, M. J., Lee, J., Chang, D. Y., Yoo, O. J.
[ 95 ]	Autoimmun Rev. 2021 Apr;20(4):102786. Risk factors for hypertension in rheumatoid arthritis patients-A systematic review. Brook Hadwen 1, Saverio Stranges 2, Lillian Barra 3.
[ 96 ]	Am J Physiol Regul Integr Comp Physiol. 2015 Nov 1; 309(9): R1074–R1077. An impaired neuroimmune pathway promotes the development of hypertension in systemic lupus erythematosus. Keisa W. Mathis.
[ 97 ]	Autoimmun Rev. 2019 Oct;18(10):102371. Systemic lupus erythematosus and hypertension. Pamela Munguia-Realpozo 1, Claudia Mendoza-Pinto 2, Cristina Sierra Benito 3, Ricardo O Escarcega 4, Mario Garcia-Carrasco 5, Socorro Mendez Martinez 6, Ivet Etchegaray Morales 7, Jose Luis Galvez Romero 8, Alejandro Ruiz-Arguelles 9, Ricard Cervera 10.
[ 98 ]	Best Pract Res Clin Rheumatol. 2017 Jun;31(3):364-372. Atherosclerosis in systemic lupus erythematosus. Sara Croca 1, Anisur Rahman 2.
[ 99 ]	J Intern Med. 2023 Jan;293(1):48-62. Systemic lupus erythematosus and cardiovascular disease. Johan Frostegård 1.
[ 100 ]	Eur J Prev Cardiol. 2015 Nov;22(11):1435-41. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Flavia Ballocca 1, Fabrizio D'Ascenzo 2, Claudio Moretti 2, Pierluigi Omedè 2, Enrico Cerrato 2, Umberto Barbero 2, Antonio Abbate 3, Maria Tiziana Bertero 4, Giuseppe Biondi Zoccai 5, Fiorenzo Gaita 2.
[ 101 ]	Ther Adv Cardiovasc Dis. 2016 Mar 15;11(1):20-32. Understanding mechanisms of hypertension in systemic lupus erythematosus. Erin B Taylor 1, Michael J Ryan 2.
[ 102 ]	The Lancet (Diabetes and Endocrinology), VOLUME 9, ISSUE 12, P876-892, DECEMBER 01, 2021. Diagnosis and treatment of primary aldosteronism. Prof Martin Reincke, MD . Irina Bancos, MD. Prof Paolo Mulatero, MD. Ute I Scholl, MD. Prof Michael Stowasser, PhD. Tracy Ann Williams, PhD.
[ 103 ]	Front Physiol. 2020; 11: 559341. Low Nitric Oxide Bioavailability Increases Renin Production in the Collecting Duct. Andrew C. Curnow,1,† Sabrina R. Gonsalez,1,2,† Venkateswara R. Gogulamudi,1 Bruna Visniauskas,1 Eric E. Simon,3 Alexis A. Gonzalez,4 Dewan S. A. Majid,1,5 Lucienne S. Lara,2 and Minolfa C. Prieto1,5,* .
[ 104 ]	Hypertension 41 42–49. Urinary Angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Kobori H., Nishiyama A., Harrison-Bernard L. M., Navar L. G. (2003).
[ 105 ]	J. Clin. Invest. 123 2011–2023. (2013). The absence of intrarenal ACE protects against hypertension. Gonzalez-Villalobos R. A., Janjoulia T., Fletcher N. K., Giani J. F., Nguyen M. T., Riquier-Brison A. D., et al.
[ 106 ]	Am J Physiol Renal Physiol. 2020 Feb 1; 318(2): F285–F297. Sox6 as a new modulator of renin expression in the kidney. Mohammad Saleem,1 Conrad P. Hodgkinson,2 Liang Xiao,1 Juan A. Gimenez-Bastida,1 Megan L. Rasmussen,3 Jason Foss,1 Alan J. Payne,2 Maria Mirotsou,2 Vivian Gama,3 Victor J. Dzau,2 and Jose A. Gomez1
[ 107 ]	Am J Physiol 259: F660–F665, 1990. Recruitment of renin gene-expressing cells in adult rat kidneys. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, Carey RM.
[ 108 ]	Am J Physiol Heart Circ Physiol 296: H1255–H1262, 2009. CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. Gomez RA, Pentz ES, Jin X, Cordaillat M, Sequeira Lopez ML.
[ 109 ]	Kidney Int 75: 460–462, 2009. Who and where is the renal baroreceptor? the connexin hypothesis. Gomez RA, Sequeira Lopez ML.
[ 110 ]	European Society of Cardiology. Journals. e-Journal of Cardiology Practice - Volume 2, Salt and hypertension: current views. Vol. 22, N° 3 - 16 Feb 2022. Dr. Ghada Sayed Youssef.
[ 111 ]	European Heart Journal, Volume 43, Issue 18, 7 May 2022, Pages 1743–1755. Sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension. Chao Zeng, Lynn Rosenberg, Xiaoxiao Li, Luc Djousse, Jie Wei, Guanghua Lei, Yuqing Zhang.
[ 112 ]	J Clin Hypertens (Greenwich). 2018 Dec; 20(12): 1654–1665. High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: A regularly updated systematic review of salt and health outcomes (August 2016 to March 2017). Daniela Malta, PhD, RD, 1 Kristina S. Petersen, PhD, APD, 2 , 3 Claire Johnson, PhD, 4 Kathy Trieu, MPH, 4 Sarah Rae, 5 Katherine Jefferson, 5 Joseph Alvin Santos.
[ 113 ]	Curr Hypertens Rep. 2020 Jan 8;22(1):2. Food Products That May Cause an Increase in Blood Pressure. Marcin Adamczak 1, Andrzej Wiecek 2
[ 114 ]	Nutrients. 2022 Mar 13;14(6):1215. A Systematic Review on Processed/Ultra-Processed Foods and Arterial Hypertension in Adults and Older People. Suamy Sales Barbosa 1 2, Layanne Cristini Martin Sousa 3, David Franciole de Oliveira Silva 3, Jéssica Bastos Pimentel 1, Karine Cavalcanti Maurício de Sena Evangelista 1 2, Clélia de Oliveira Lyra 1 2, Márcia Marília Gomes Dantas Lopes 1 2, Severina Carla Vieira Cunha Lima 1 2.
[ 115 ]	Endocrinol Metab Clin North Am. 2019 Dec;48(4):859-873. Drug-Induced Hypertension. Matthew C Foy 1, Joban Vaishnav 2, Christopher John Sperati 3 .
[ 116 ]	Circ Res. 2021 Apr 2; 128(7): 1040–1061. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Daan C.H. van Dorst,1,2,* Stephen J.H. Dobbin,4,* Karla B. Neves,4 Joerg Herrmann,5 Sandra M. Herrmann,6 Jorie Versmissen,1,3 Ron H.J. Mathijssen,2 A.H. Jan Danser,1 and Ninian N. Lang4 .
[ 117 ]	Curr Oncol Rep. 2022 Apr; 24(4): 463–474. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Nicholas Camarda,1 Richard Travers,1,2 Vicky K. Yang,3 Cheryl London,3 and Iris Z. Jaffe1 .
[ 118 ]	Nephrol Dial Transplant. 2018 Oct 1;33(10):1690-1698. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Rajiv Agarwal 1 .
[ 119 ]	European Journal of Pharmacology. September 2015, Pages 15-22. Drug induced hypertension – An unappreciated cause of secondary hypertension. Franz H. Messerli b, Ehud Grossman c .
[ 120 ]	Eur J Prev Cardiol. 2017 Nov;24(17):1833-1840. Effect of marijuana use on cardiovascular and cerebrovascular mortality: A study using the National Health and Nutrition Examination Survey linked mortality file. Barbara A Yankey 1, Richard Rothenberg 1, Sheryl Strasser 1, Kim Ramsey-White 1, Ike S Okosun 1.
[ 121 ]	Hypertens Pregnancy. 2005;24(2): 103-15.MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Jenny E Myers 1, Shaila J Merchant, Maureen Macleod, Gary J Mires, Philip N Baker, Sandra T Davidge.
[ 122 ]	Reprod Biol Endocrinol. 2009; 7: 85. Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Michal Lavee,1 Shlomit Goldman,1 Etty Daniel-Spiegel,1 and Eliezer Shalev1,2 .
[ 123 ]	Cardiovasc Hematol Agents Med Chem. 2010 Oct 1; 8(4): 204–226. Molecular and Vascular Targets in the Pathogenesis and Management of the Hypertension Associated with Preeclampsia. Ossama M. Reslan and Raouf A. Khalil.
[ 124 ]	Acta Physiol (Oxf). 2013 Jul; 208(3): 224–233. Pathophysiology of Hypertension in Preeclampsia: A Lesson in Integrative Physiology. Ana C. Palei,1,2 Frank T. Spradley,1,2 Junie P. Warrington,1,2 Eric M. George,1,2 and Joey P. Granger1,2 .
[ 125 ]	Acta Obstet Gynecol Scand. 2014; 93:959–64. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Seki H.
[ 126 ]	Hypertension. 2020; 75:1363–81. Animal models of pre-eclampsia: causes, consequences, and interventions. Gatford KL, Andraweera PH, Roberts CT, Care AS.
[ 127 ]	Hypertension. 2008 Apr; 51(4): 982–988. Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia. Babbette D. LaMarca, Jeffery Gilbert, and Joey P. Granger.
[ 128 ]	Am J Hypertens. 2020 Jul 18;33(7):583-594.Uric Acid and Hypertension: An Update With Recommendations. Laura G Sanchez-Lozada 1, Bernardo Rodriguez-Iturbe 1 2, Eric E Kelley 3, Takahiko Nakagawa 4, Magdalena Madero 1, Dan I Feig 5, Claudio Borghi 6, Federica Piani 1 6, Gabriel Cara-Fuentes 7, Petter Bjornstad 8, Miguel A Lanaspa 9, Richard J Johnson 9 .
[ 129 ]	Int J Mol Sci. 2021 Nov; 22(22): 12394. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Yoshitaka Kimura,1,2 Daisuke Tsukui,1 and Hajime Kono1 .
[ 130 ]	2015 Nov 30;10(11): Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study. Hai-Lun Sun 1, Dee Pei 2, Ko-Huang Lue 1, Yen-Lin Chen 3 .
[ 131 ]	Nucleosides Nucleotides Nucleic Acids. 2011; 30:1039–1044. Relationship between Hyperuricemia and Chronic Kidney Disease. Ohno I.
[ 132 ]	Nephrology (Carlton). 2020 Sep;25(9):691-699. Associations between nephrolithiasis and diabetes mellitus, hypertension and gallstones: A meta-analysis of cohort studies. Bing-Biao Lin 1 2, Rong-Hua Huang 2 3, Bing-Liang Lin 4, Ying-Kai Hong 1, Ming-En Lin 1, Xue-Jun He 1.
[ 133 ]	Pol Arch Intern Med. 2017 Mar 1;127(3):195-204. Recent advances in the pathophysiology of arterial hypertension: potential implications for clinical practice. Dagmara Hering, Andrzej Trzebski, Krzysztof Narkiewicz.